COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients (EGF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02187367
Recruitment Status : Terminated (Sponsor decision based on slow recruitment and new emerging drug combinations)
First Posted : July 11, 2014
Last Update Posted : September 10, 2019
Information provided by (Responsible Party):
Bioven Sdn. Bhd. ( Bioven Europe )

Brief Summary:
The vaccine contains humanized recombinant antigen (EGF - Epithelial Growth Factor) and an adjuvant. The antibodies induced by vaccination will react with circulating EGF leading to removal of EGF from the circulation. As a result, binding to its target EGF-Receptor is prevented. Blocking of EGF-Receptor is preventing activation and stimulation of proliferation of tumour cell. A Phase 3 clinical trial on the EGF vaccine is ongoing in Cuba. The result from previous studies demonstrated positive correlation between extended survival and immune response against the vaccination in the late-stage NSCLC patients' age below 60 with improved quality of life. The purpose of this international Phase 3 trial is to determine whether the recombinant human EGF cancer vaccine is safe, immunogenic and effective in the treatment of stage IV NSCLC patients who are positive in the selective EGF biomarker and wild type EGF-Receptor compared to standard treatment and supportive care.

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Biological: EGF Vaccine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 106 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care
Actual Study Start Date : May 2015
Actual Primary Completion Date : May 1, 2019
Actual Study Completion Date : September 6, 2019

Arm Intervention/treatment
Experimental: EGF Vaccine
Patients in this arm will receive a low dose of cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51
Biological: EGF Vaccine
1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
Other Name: Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51

No Intervention: Best Supportive Care
Patients in this arm will receive best supportive care

Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Each patient will be followed till death occurs within study time frame of 3 years ]
    To assess overall survival (OS) of an EGF cancer vaccine in inoperable, stage IV biomarker positive, wild type EGF-R, NSCLC patients compared to the control group receiving best treatment and supportive care. OS is defined as the time from randomisation to death due to any cause.

Secondary Outcome Measures :
  1. Safety of EGF Cancer Vaccine as assessed by Adverse Events (AEs) [ Time Frame: Each patient will be followed till death occurs within study time frame of 3 years ]
    To assess the frequency and number of patients develop AEs, related AEs, serious AEs (SAEs) and AEs leading to withdrawal or death

  2. Progression-Free Survival (PFS) [ Time Frame: Each patient will be followed till objective tumour progression or death (whichever occurs first) within time frame of study of 3 years ]
    Progression parameters include radiological or clinical progression, withdrawal due to progression, and death due to any cause.

  3. Survival Rate [ Time Frame: Each patient will be followed at 12 and 24 months after randomization ]
    To assess the percentage of patients that are alive at 12 months and 24 months in EGF cancer vaccine study group compared to control group.

  4. Time to Progression (TTP) [ Time Frame: Each patient will be followed till observed tumour progression within study time frame of 3 years ]
    To assess Time to Progression (TTP) from the time of randomisation to first documented disease progression of EGF cancer vaccine study group patients compared to control group.

  5. Response Rate (RECIST criteria) [ Time Frame: Each patients will be followed till death occurs within study time frame of 3 years ]
    To assess the percentage of patients with a complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria Version 1.1.

  6. Safety of EGF Cancer Vaccine by Laboratory Assessment [ Time Frame: Each patients will be followed till death occurs within study time frame of 3 years ]
    To assess haematology, biochemistry and urinalysis parameters

  7. Safety of EGF Cancer Vaccine assessed by Vital Signs [ Time Frame: Each patients will be followed till death occurs within study time frame of 3 years ]
    To assess systolic and diastolic blood pressure, body temperature and pulse rate

  8. Safety of EGF Cancer Vaccine as assessed by Physical Examination [ Time Frame: Each patient will be followed till death occurs within study time frame of 3 years ]
    To assess eyes, neurological and cardiovascular systems, lungs, abdomen, and any other areas with signs and symptoms of disease, and of the head, neck, ears, nose, mouth, throat, thyroid, lymph nodes and extremities

  9. Quality of Life (QoL) [ Time Frame: Each patient will be followed till death occurs within study time frame of 3 years ]
    To assess the general physical health of patients with a 36-item, short-form health survey until disease progression

Other Outcome Measures:
  1. Pharmacodynamics (PD) of EGF Cancer Vaccine assessed by Immune Responses [ Time Frame: Each patients will be followed till death within study time frame of 3 years ]
    To assess the serum EGF concentration and anti-EGF antibody titers with response before and after to the study treatment

  2. Efficacy assessed by KRAS and ALK rearrangements [ Time Frame: At time of screening ]
    For the analysis of oncogenes Kirsten rat sarcoma (KRAS) and anaplastic lymphoma kinase (ALK), a formalin-fixed, paraffin embedded (FFPE) sample of the biopsy tumour tissue, ideally taken from biopsy obtained at disease diagnosis will be prepared and shipped for central analysis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Are aged 18 or older.
  2. Have serum EGF concentration >250 pg/ml determined from sample taken at screening.
  3. Have wild type EGF-R sequence.
  4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  5. Have adequate bone marrow, liver and renal function, as assessed by the Investigator. A sample taken at Screening should confirm that:

    • White blood cell (WBC) count ≥ 3000 per µL
    • Platelet count ≥ 100,000 per µL
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) (or ≤ 5 x ULN when liver metastases are present)
    • Total bilirubin ≤ 1.5 x ULN
    • Serum creatinine ≤ 1.5 x ULN
  6. Have histologically and/or cytologically confirmed diagnosis of NSCLC, corresponding to locally and regionally advanced inoperable disease (Stage IV [as defined by the American Joint Committee on Cancer staging system- TNM 7th edition 2010]) excluding brain metastases.
  7. Are eligible to receive first-line chemotherapy (without concurrent radiotherapy to thorax measurable lesions or consolidation radiotherapy).
  8. Agree to use double-barrier contraception (males and females alike [if applicable]). A negative pregnancy test must be documented at Screening for females of childbearing potential.

    Note: Females of childbearing potential are defined as those women with less than 2 years after last menstruation and not surgically sterile, while post-menopausal refers to those women with at least 2 years from last menstruation.

  9. Have signed a voluntary written informed consent form (ICF). Patients should be cooperative, willing and able to participate and adhere to the Protocol requirements, including their availability for the follow-up.

Exclusion Criteria:

  1. Patient has no measurable disease (as defined by RECIST Criteria, version 1.1).
  2. Patient has EGF-R mutation.
  3. Patient has EGF serum concentration below required threshold.
  4. Patient is a candidate for concurrent chemo-radiotherapy or post chemo thoracic radiotherapy.
  5. Patient has a history of known or suspected central nervous system (CNS) metastases.
  6. Patient has a history of primary malignancy (except resected non-melanoma skin cancer or curatively treated carcinoma in situ of the cervix), unless in complete remission and off all chemotherapy and/or radiotherapy for that disease for a minimum of 5 years. Any palliative radiotherapy to alleviate pain in bone metastases is permitted.
  7. Patient is taking immunosuppressant drugs such as azathioprine, tacrolimus, cyclosporine, etc. Use is not permitted within 1 month before Screening.
  8. Patient is taking any other immunotherapy.
  9. Patient has primary or secondary immunodeficiencies (e.g. documented Human Immunodeficiency Virus [HIV]).
  10. Patient has autoimmune disease.
  11. Patient has undergone splenectomy.
  12. Patient is taking oral, intramuscular or intravenous corticosteroids. Use is not permitted within 1 month before Screening. Inhaled corticosteroids to treat respiratory insufficiency (e.g. chronic obstructive pulmonary disease [COPD]), or topical steroids are permitted.
  13. Patient has neurotoxicity (Grade ≥2).
  14. Patient has diarrhoea (Grade ≥2).
  15. Patient has received other vaccines (with the exception of the influenza vaccine), within 1 month before Screening.
  16. Patient has a history of any severe or life-threatening hypersensitivity reaction.
  17. Patient has an unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal and metabolic disease).
  18. Patient has recent history (within 6 months before Screening) of chronic alcohol or drug abuse which may compromise the patient's safety or ability to participate in study activities.
  19. Patient has a history of psychiatric disorder that prevents patients from providing informed consent or following Protocol instructions.
  20. Patient is currently enrolled in an investigational device or drug trial, or <1 month since completing an investigational device or drug trial.
  21. Female patients who are pregnant or lactating.
  22. Patient has any other factor that in the opinion of the Investigator (or designee) would make the patient unsafe or unsuitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02187367

Hide Hide 51 study locations
Layout table for location information
"Multiprofile Hospital for Active Treatment (MHAT)-Dobrich" AD
Dobrich, Bulgaria
MHAT for Women's Health-Nadezhda"OOD
Sofia, Bulgaria
Nemocnice Na Pleši s.r.o. Oddelení klinické onkologie a radioterapie
Nová Ves pod Pleší, Czechia
Pardubická krajská nemocnice, a.s.c
Pardubice, Czechia
Thomayerova nemocnice
Prague, Czechia
Cancer Center of Adjara
Batumi, Georgia
Clinic Health House
Tbilisi, Georgia
Institute of Clinical Oncology
Tbilisi, Georgia
JSC, Maritime Hospital
Tbilisi, Georgia
JSC, Neo Medi
Tbilisi, Georgia
LTD, High Technology Medical Centre, University Clinic
Tbilisi, Georgia
LTD, Medulla - Chemotherapy and Immunotherapy Clinic
Tbilisi, Georgia
Research Institute Of Clinical Medicine
Tbilisi, Georgia
Universitätsklinikum Halle (Saale) Klinik und Poliklinik fuer Innere Medizin
Halle, Saale, Germany
Augusta-Kranken-Anstalt Bochum
Bochum, Germany
KRH Klinikum Siloah Hannover - Oststadt
Hannover, Germany
Thoraxklinik Heidelberg gGmbH
Heidelberg, Germany
Universitätsklinikum Schleswig-Holstein (UKSH)
Kiel, Germany
Kliniken der Stadt Köln GmbH
Köln, Germany
Universitätsklinikum Leipzig - AöR
Leipzig, Germany
München, Germany
Oststeinbek, Germany
Hospital Sultanah Bahiyah
Alor Setar, Kedah, Malaysia
Sarawak General Hospital
Kuching, Malaysia
Mahkota Medical Center
Malacca, Malaysia
Hospital Pulau Pinang
Pulau Pinang, Malaysia
Perpetual Succour Hospital
Lahug, Cebu City, Philippines
Makati Medical Center
Makati, Manila, Philippines
The Medical City
Pasig, Metro Manila, Philippines
Lung Center of the Philippines
Quezon City, Metro Manila, Philippines
Davao Doctors hospital
Davao City, Philippines
Cancer Research Center
Manila, Philippines
Philippine General Hospital
Manila, Philippines
Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc
Olsztyn, Poland
Szpital Specjalistyczny w Prabutach
Prabuty, Poland
Centrul de Oncologie "Sf. Nectarie"
Craiova, Romania
S.C. R.T.C. Radiology Therapeutic Center S.R.L.
Otopeni, Romania
SC Oncomed SRL
Târgu-Mureş, Romania
Hospital Universitario Quiron Dexeus
Barcelona, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario Fundación Jimenez Díaz
Madrid, Spain
Hospital Universitario Puerta de Hierro
Madrid, Spain
Hospital Regional Universitario de Málaga
Málaga, Spain
Lopburi Cancer Hospital
Mueang, Lopburi, Thailand
Songklanagarind Hospital
Hat Yai, Songkhla, Thailand
Bangkok Hospital Chiang Mai
Bangkok, Thailand
Lampang Cancer Hospital
Lampang, Thailand
Buddhachinaraj Hospital
Phitsanulok, Thailand
United Kingdom
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Nottingham University Hospitals
Nottingham, United Kingdom
University Hospital Southampton NHS Trust
Southampton, United Kingdom
Sponsors and Collaborators
Bioven Europe
Layout table for investigator information
Principal Investigator: Libor Havel, Dr. Thomayerova nemocnice, Czech Republic

Layout table for additonal information
Responsible Party: Bioven Europe Identifier: NCT02187367    
Other Study ID Numbers: BV-NSCLC-002
2013-005335-25 ( EudraCT Number )
First Posted: July 11, 2014    Key Record Dates
Last Update Posted: September 10, 2019
Last Verified: September 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists